MET has also been described as a potential therapeutic target for multiple myeloma (MM), where Akt/mTOR is a crucial signaling component through which Met protects multiple myeloma cells from chemotherapy-induced growth inhibition and apoptosis. Here, MTOR is linked to AL amyloidosis.